Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

5541 - Relationship between ethnicity and overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib (S): Results from a Canadian multi-centre HCC database

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Cancer Prevention

Tumour Site

Hepatobiliary Cancers

Presenters

Daniel Meyers

Citation

Annals of Oncology (2018) 29 (suppl_8): viii205-viii270. 10.1093/annonc/mdy282

Authors

D.E. Meyers1, R. Lee-Ying1, M. Alghamdi1, H. Sim2, V.O. Zaborska3, Y. Ko4, T. Raycraft3, E. Batuyong1, W.Y. Cheung1, H. Samawi1, J.M. Davies3, V.C. Tam1

Author affiliations

  • 1 Medical Oncology, Tom Baker Cancer Centre, T2N 4N2 - Calgary/CA
  • 2 Oncology, Princess Margaret Cancer Center, M5G 2M9 - Toronto/CA
  • 3 Faculty Of Medicine, University of British Columbia, V1Y 1T3 - Vancouver/CA
  • 4 Sunnybrook Health Sciences Centre, Odette Cancer Centre, M4N 3M5 - Toronto/CA

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5541

Background

The SHARP and Asia-Pacific (AP) trials showed that S improves OS compared to placebo in advanced HCC. However, OS was worse in the AP trial, which included predominantly East Asian (EA) patients. The purpose of this study was to determine whether ethnicity affects OS in patients with advanced HCC being treated with S.

Methods

Patients who received S for the treatment of HCC between 01/01/08 and 30/06/16 in the provinces of British Columbia and Alberta, as well as Princess Margaret Cancer Centre and Sunnybrook Odette Cancer Centre in Toronto, Ontario were included. Patient demographics and clinical variables were retrospectively collected. Patients were dichotomized by ethnicity as either EA or not according to a validated list of surnames. Survival outcomes were assessed with Kaplan-Meier curves and compared with the log-rank test. A Cox-proportional hazard model was constructed with ethnicity and relevant clinical characteristics to assess their impact on survival.

Results

A total of 757 patients were included. Mean age was 64 years. 81% men, 36% East Asian, and 86% Child-Pugh (CP) A at initiation of S. Underlying cause of liver disease was 31% hepatitis B Virus (HBV) and 30% hepatitis C virus (HCV). Majority of patients had a performance status of 0 (30%) or 1 (58%). EA compared to non-EA were more likely to have HBV (68 vs 11%) and less likely to have HCV (13 vs 39%), p < 0.01. Median OS was 8.6 months for EAs and 9.6 months in non-EAs (p = 0.89). On multivariate analysis, ethnicity (HR 1.01, 95% CI 0.82 – 1.27, p = 0.89) was not a significant prognostic factor for OS. However, no previous localized treatment (HR 1.66 95%CI 1.39 - 1.99, p < 0.01), higher ECOG (HR 1.63 95% CI 1.34-1.97. p < 0.01), CP B at initiation of S (HR 1.72 95% CI 1.34 - 2.20, p < 0.01) and HBV compared to HCV (HR 1.39 95% CI 1.08-1.80, p = 0.01) were associated with worse survival.

Conclusions

Ethnicity does not affect OS in HCC patients treated with S. However, patients treated with S who have a history of HCV appear to have a better OS than those with HBV. Higher baseline ECOG, no previous localized treatments and CP B liver function appear to negatively affect OS.

Clinical trial identification

Legal entity responsible for the study

CHORD consortium.

Funding

Department of Oncology, University of Calgary.

Editorial Acknowledgement

Disclosure

J.M. Davies: Advisory capacity: Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.